What Is the Life Expectancy of Someone With Turner Syndrome?

Women with Turner syndrome live, on average, somewhere between 8 and 13 years fewer than the general female population, though that gap appears to be narrowing as medical care improves. A Danish national cohort study published in 2024 found a median survival roughly 8 years shorter than matched controls, while an older British prospective study estimated the reduction at about 13 years from age one.¹² The difference between those estimates likely reflects decades of progress in screening, hormone therapy, and cardiac surveillance. Still, cardiovascular disease remains the overwhelming driver of early death, and understanding the specific risks that shorten life is the first step toward managing them.

Cardiovascular Disease Is the Main Reason Life Expectancy Falls Short

When researchers study what actually kills women with Turner syndrome earlier than expected, cardiovascular problems dominate the list. A 68-year follow-up study found that survival at 30 years was about 82% for women with Turner syndrome compared with 94% for age-matched controls, and cardiovascular disease was the leading cause of death.³ The 2024 Danish cohort study confirmed this, reporting that the risk of dying from circulatory disease was about nine times higher than in control women, and the risk specifically from aortic dissection was over 20 times higher.¹

Aortic dissection is probably the single most feared complication. This is when the wall of the aorta tears, and it can be fatal within minutes if not treated. In young and middle-aged women with Turner syndrome, the risk of acute aortic dissection is estimated to be more than 100-fold higher than in the general population.⁴ This risk is closely tied to congenital heart defects that are extremely common in Turner syndrome. Nearly half of women with the condition have a bicuspid aortic valve, a structural difference where the aortic valve has two flaps instead of the usual three.⁵ An international registry of aortic dissections in Turner syndrome found that 95% of spontaneous dissections occurred in women who had an underlying cardiac malformation, most commonly a bicuspid aortic valve.⁶

Beyond these structural problems, the American Heart Association has highlighted that early-onset high blood pressure, ischemic heart disease, and stroke are major factors reducing lifespan in Turner syndrome.⁷ A 12-year study tracking blood pressure in women with Turner syndrome found that both systolic and diastolic blood pressure rose over time, pushing the cardiovascular risk profile higher with each passing year.⁸ High blood pressure on its own accelerates aortic widening, which makes dissection more likely. This is why regular cardiac imaging and aggressive blood pressure management are central to modern Turner syndrome care.

How Karyotype Shapes the Outlook

Turner syndrome is not one single genetic picture. The classic form involves a complete loss of one X chromosome (written as 45,X), but many women have mosaic forms where some cells have the typical two sex chromosomes and others do not. This distinction matters for health outcomes. A large population study found that women with nonmosaic 45,X were, on average, about 17 cm shorter than women with two intact X chromosomes, while women with the mosaic 45,X/46,XX form were only about 4 cm shorter. Some mosaic women were actually taller than the average woman in the general population.⁹ Height itself is not a direct predictor of lifespan, but it serves as a rough proxy for how much the missing X chromosome material is affecting the body overall. Mosaic Turner syndrome generally comes with milder manifestations of the cardiovascular, metabolic, and structural complications that drive mortality.

A separate and rarer concern applies to women whose Turner syndrome karyotype includes fragments of a Y chromosome. In a series of 18 consecutive patients with this variant, tumors were found in the gonadal tissue of a third, including both gonadoblastoma and a more aggressive cancer called dysgerminoma.¹⁰ This is why genetic testing to check for Y-chromosome material is standard, and preventive removal of the gonadal tissue is recommended when it is found.

Diabetes and Metabolic Risks

Cardiovascular disease may be the headline killer, but metabolic problems lurk close behind and feed into the cardiovascular risk. Diabetes is considerably more common in Turner syndrome than in the general female population, and when it does develop, it hits harder. One review found that diabetes in women with Turner syndrome was associated with an 11-fold increase in mortality.¹¹ That is a staggering multiplier that suggests diabetes in this population is not simply the same disease behaving the same way.

Part of the explanation may be the pattern of insulin resistance seen in affected women. A study comparing women with Turner syndrome and diabetes to those with normal glucose tolerance found that insulin resistance was present in over half of the women with Turner syndrome-associated diabetes, compared with only about 6% of women with Turner syndrome and normal glucose levels.¹² Higher body mass index and greater central body fat both independently predicted glucose problems. A real-world cohort study found that about 7% of Turner syndrome patients carried a diabetes diagnosis.¹³

The liver is another metabolic organ that seems to take a hit. Women with Turner syndrome have been found to carry higher levels of liver enzymes and markers of liver fibrosis compared to controls.¹⁴ Liver disease was one of the leading causes of death in the 68-year follow-up study mentioned earlier, alongside cardiovascular disease and cancer.³ The relationship between hormonal imbalances, chronic low-grade inflammation, and liver damage in Turner syndrome is still being untangled, but the clinical message is clear: liver function should be monitored regularly.

The Autoimmune Burden

Women with Turner syndrome face roughly double the risk of autoimmune diseases compared with the general female population.¹⁵ The most common autoimmune condition is thyroid disease: a meta-analysis estimated that about a quarter of women with Turner syndrome develop Hashimoto’s thyroiditis, the most frequent cause of hypothyroidism.¹⁶ Untreated hypothyroidism adds its own cardiovascular strain by raising cholesterol and promoting weight gain, so catching it early through routine antibody screening matters for the broader survival picture.

Celiac disease is the second most common autoimmune finding. A meta-analysis of over 6,000 Turner syndrome patients estimated a celiac disease prevalence of about 4.5 to 6%, depending on how the data were pooled.¹⁷¹⁶ That rate is several times higher than the roughly 1% prevalence in the general population. The same meta-analysis also flagged type 1 diabetes at about 1.3% and Crohn’s disease at about 1.1%.¹⁶ None of these conditions is individually a major killer, but together they add layers of chronic illness that can affect nutrition, energy, and overall resilience.

Cancer Risk Has a Distinctive Pattern

One piece of good news is that the overall risk of cancer does not appear to be elevated in Turner syndrome. A large study found a hazard ratio for cancer of essentially 1.0, meaning no meaningful increase compared to the general population.¹⁸ Breast cancer risk is actually lower, with the hazard ratio roughly halved. This may relate to the reduced lifetime estrogen exposure that comes with ovarian insufficiency.

The pattern is not uniformly favorable, though. Women with the classic 45,X karyotype showed a two- to five-fold increased risk of certain cancers including colon and rectal cancers, skin cancers, and benign tumors of the central nervous system.¹⁸ A separate British national cohort study identified increased risks of meningioma and childhood brain tumors, along with possible increases in bladder cancer and melanoma.¹⁹ These specific cancers are rare enough that the absolute risk to any individual is still low, but they justify some degree of heightened screening awareness.

Kidney and Bone Health

About a third of women with Turner syndrome have some kind of kidney structural difference. Two separate studies found renal anomalies in roughly 32 to 35% of patients, with horseshoe kidney being the most common.²⁰²¹ The reassuring finding is that kidney function, even in those with structural differences, did not deteriorate to the point of chronic kidney disease during a median follow-up of about eight years.²¹ These anomalies are still worth knowing about because they can predispose to urinary tract infections or occasionally complicate surgical planning, but they are not a major driver of mortality.

Bone health is a more pressing concern for longevity. Women with Turner syndrome have lower bone mineral density and a higher fracture rate than healthy individuals, with the primary risk factor being undertreated ovarian insufficiency.²² There appears to be about a 25% increase in fracture risk, mainly affecting the long bones of the forearm, which may reflect a selective deficiency in the outer layer of bone that exists independently of estrogen levels.²³ After age 45, lack of adequate estrogen replacement can also weaken the spongy interior bone of the spine, leading to vertebral compression fractures. Fractures themselves rarely kill, but in older age, hip and spinal fractures are associated with a cascade of immobility and complications that can shorten life.

Pregnancy and Aortic Risk

Most women with Turner syndrome experience premature ovarian insufficiency and need assisted reproduction (typically donor eggs) to become pregnant. Pregnancy is possible but carries a uniquely dangerous cardiac risk. The American Society for Reproductive Medicine has stated that the risk of death from aortic dissection or rupture during pregnancy in women with Turner syndrome may be as high as 1%.²⁴ For context, a 1-in-100 chance of a life-threatening aortic event is extraordinarily high in obstetric terms. The committee opinion classifies Turner syndrome as a relative contraindication for pregnancy in general, and an absolute contraindication when the aorta is enlarged beyond certain thresholds or when other cardiac anomalies are present.²⁴ Any woman with Turner syndrome considering pregnancy needs thorough cardiac imaging and counseling well before conception.

Hormonal Therapies That Affect Long-Term Health

Two hormonal therapies form the backbone of Turner syndrome management, and both have implications for lifespan. Growth hormone is given during childhood to address the characteristic short stature. A systematic review found that growth hormone therapy allows girls with Turner syndrome to reach appropriate adult heights compared to what their final height would have been without treatment, with the biggest gains occurring during the prepubertal years.²⁵ Growth hormone itself is primarily about height and quality of life rather than mortality, but early diagnosis and initiation of treatment signals that a patient is plugged into the kind of coordinated care that does affect survival.²⁶

Estrogen replacement therapy has a more direct impact on long-term health. Because the ovaries typically fail early, most women with Turner syndrome need estrogen to go through puberty and to maintain bone and cardiovascular health throughout adulthood. Current guidance recommends starting estrogen between ages 11 and 12, increasing gradually over two to three years to mimic natural puberty.²⁷ A meta-analysis confirmed that estrogen replacement significantly increases bone mineral density during treatment, helping to reduce fracture risk.²⁸ Estrogen replacement also lowers blood pressure, which feeds directly into the cardiovascular risk equation.²⁷ Women who stop or skip estrogen replacement lose these protective benefits, which is one reason that maintaining consistent hormone therapy into adulthood is stressed by endocrinologists.

Quality of Life and Psychosocial Wellbeing

Lifespan tells you how many years someone lives. It does not tell you much about what those years feel like. Research consistently shows that women with Turner syndrome report lower quality of life than the general population, with greater levels of stress and fatigue identified as key contributors.²⁹ A Dutch study that measured a broad range of psychosocial variables found significant differences in anxiety, depression, self-esteem, social participation, and symptoms overlapping with ADHD and autism spectrum traits.³⁰ The strongest predictors of quality of life turned out to be depression, satisfaction with income, and self-esteem, rather than the medical complications themselves.

That finding matters practically. It suggests that mental health support, career counseling, and building social connections are not just nice additions to medical care; they are among the most effective levers for improving how women with Turner syndrome actually experience their lives. The number of working hours and satisfaction with income did not differ significantly from controls, which means many women with Turner syndrome are fully engaged in work and find it financially adequate.³⁰ The gap is more about internal wellbeing than external achievement, and that is a gap that targeted psychological support can narrow.

Why the Gap May Be Shrinking

The range of estimates for reduced life expectancy (8 to 13 years) partly reflects different eras of medicine. The British study estimating a 13-year reduction was published in 1986 and followed patients whose care predated routine cardiac MRI, modern blood pressure drugs, and standardized estrogen protocols.² The 2024 Danish study, with its 8-year estimate, captures patients who benefited from at least some of those advances.¹ Neither study reflects the care available to a girl diagnosed today, who might grow up with routine aortic surveillance starting in childhood, early growth hormone treatment, physiologically timed estrogen replacement, screening for thyroid disease and celiac disease, and metabolic monitoring to catch diabetes before it causes damage.

There is no published study yet that can calculate the life expectancy of someone diagnosed in infancy in 2025 and given optimal multidisciplinary care throughout life. The honest answer is that we do not know whether the gap will close to five years, three years, or something smaller. What the evidence does show is that the causes of early death in Turner syndrome are increasingly things that medicine can detect and manage, even if it cannot eliminate them entirely. Aortic dissection remains the wild card because it can happen suddenly even with good surveillance, but every other major contributor to mortality, from high blood pressure to diabetes to osteoporosis, responds to treatment that is already widely available.

1
PubMed. All-cause mortality and death by aortic dissection in women with Turner syndrome: A national clinical cohort study
2
PubMed Central. Mortality ratios, life expectancy, and causes of death in patients with Turner’s syndrome
3
PubMed Central. Long-Term Outcomes in Patients With Turner Syndrome: A 68-Year Follow-Up
4
PubMed Central. Aortic dissection in Turner syndrome
5
European Heart Journal. The contribution of X-chromosome genomic imprinting to the bicuspid aortic valve and aortic coarctation prevalence in women with Turner syndrome
6
PubMed. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome
7
PubMed. Cardiovascular Health in Turner Syndrome: A Scientific Statement From the American Heart Association
8
PubMed. Natural History of Hypertension in Turner Syndrome During a 12-Year Pragmatic Interventional Study
9
Nature (Genetics in Medicine). Mosaic Turner syndrome shows reduced penetrance in an adult population study
10
PubMed. Deferring gonadectomy in patients with turner syndrome with a genetic Y component is not a safe practice
11
PubMed Central. Hyperglycemia in Turner syndrome: Impact, mechanisms, and areas for future research
12
The Journal of Clinical Endocrinology & Metabolism. Characterization of Turner Syndrome-associated Diabetes Mellitus
13
Medicina Clínica (English Edition). Metabolic profiles of Turner syndrome: A real-world cohort study
14
PubMed Central. Elevated Liver Enzymes in Turner Syndrome: The Role of Low-grade Inflammation and Hormonal Imbalances
15
PubMed Central. Autoimmune diseases in Turner syndrome: an overview
16
PubMed Central. Global prevalence of autoimmune diseases in turner syndrome: a systematic review and meta-analysis
17
PubMed Central. Prevalence of Celiac Disease in Patients With Turner Syndrome: Systematic Review and Meta-Analysis
18
PubMed. Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy
19
PubMed. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study
20
PubMed. Renal malformations in patients with Turner syndrome: imaging in 141 patients
21
PubMed. Renal morphology and function from childhood to adulthood in Turner syndrome
22
PubMed. Turner syndrome and osteoporosis
23
PubMed. Fracture risk and bone mineral density in Turner syndrome
24
PubMed. Maternal cardiovascular morbidity and mortality associated with pregnancy in individuals with Turner syndrome: a committee opinion
25
PubMed. Growth Hormone Treatment to Final Height in Turner Syndrome: Systematic Review
26
Advances in Pharmacology and Clinical Trials. Early Diagnosis and Multidisciplinary Management of Turner Syndrome: A Paediatric Case Study
27
The Journal of Clinical Endocrinology & Metabolism. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations
28
PubMed Central. Effect of Growth Hormone and Estrogen Replacement Therapy on Bone Mineral Density in Women with Turner Syndrome: A Meta-Analysis and Systematic Review
29
PubMed Central. How Does Turner Syndrome Affect Quality of Life? A Systematic Review
30
PubMed. Psychosocial well-being and quality of life in women with Turner syndrome